Sergolexole

Sergolexole (LY-281,067) is an ergoline derivative which acts as a selective antagonist of the serotonin 5-HT2 receptors. It has been used for various research applications, but never developed for medical use.[1][2][3]

Sergolexole
Identifiers
CAS Number
PubChem CID
Chemical and physical data
FormulaC26H36N2O3
Molar mass424.585 g·mol−1
3D model (JSmol)

References
  1. Cohen ML, Fuller RW, Kurz KD, Parli CJ, Mason NR, Meyers DB, et al. (January 1988). "Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067". The Journal of Pharmacology and Experimental Therapeutics. 244 (1): 106–12. PMID 3335993.
  2. Cohen ML, Parli CJ, Fuller RW (December 1989). "5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067)". The Journal of Pharmacology and Experimental Therapeutics. 251 (3): 1006–11. PMID 2600800.
  3. Koba S, Pakala R, Watanabe T, Katagiri T, Benedict CR (November 1999). "Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins". Journal of the American College of Cardiology. 34 (5): 1644–51. doi:10.1016/s0735-1097(99)00349-6. PMID 10551718.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.